Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (171-180 of 868) with videos related to

Pageof 87
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2005
Proteasome inhibition as a novel therapeutic target in human cancerS Vincent Rajkumar, Paul G Richardson, Teru Hideshima, et al.
Oncogene|February 7, 2020
Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myelomaArghya Ray, Yan Song, Ting Du, et al.
Leukemia & Lymphoma|May 3, 2008
Thalidomide and lenalidomide: Mechanism-based potential drug combinationsSonia Vallet, Antonio Palumbo, Noopur Raje, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 23, 2008
Individualizing treatment of patients with myeloma in the era of novel agentsJesús San-Miguel, Jean-Luc Harousseau, Douglas Joshua, et al.
Nature Clinical Practice. Oncology|June 11, 2008
Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myelomaNikhil C Munshi, Constantine Mitsiades, Paul G Richardson, et al.
Leukemia|May 20, 2020
Proteomic analysis identifies mechanism(s) of overcoming bortezomib resistance via targeting ubiquitin receptor Rpn13Ting Du, Yan Song, Arghya Ray, et al.
British Journal of Haematology|June 27, 2007
A strategic framework for novel drug development in multiple myelomaKenneth C Anderson, Alison L Hannah, Richard Pazdur, et al.
British Journal of Haematology|September 10, 2011
Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disordersJooeun Bae, Yu-Tzu Tai, Kenneth C Anderson, et al.
Oncology (Williston Park, N.Y.)|April 2, 2014
The heavy chain diseases: clinical and pathologic featuresGiada Bianchi, Kenneth C Anderson, Nancy Lee Harris, et al.
Nature Reviews. Clinical Oncology|November 26, 2014
Current treatment landscape for relapsed and/or refractory multiple myelomaMeletios A Dimopoulos, Paul G Richardson, Philippe Moreau, et al.
Pageof 87

Showing results (171-180 of 868) with videos related to

Sort By:
Pageof 87
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2005
Proteasome inhibition as a novel therapeutic target in human cancerS Vincent Rajkumar, Paul G Richardson, Teru Hideshima, et al.
Oncogene|February 7, 2020
Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myelomaArghya Ray, Yan Song, Ting Du, et al.
Leukemia & Lymphoma|May 3, 2008
Thalidomide and lenalidomide: Mechanism-based potential drug combinationsSonia Vallet, Antonio Palumbo, Noopur Raje, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 23, 2008
Individualizing treatment of patients with myeloma in the era of novel agentsJesús San-Miguel, Jean-Luc Harousseau, Douglas Joshua, et al.
Nature Clinical Practice. Oncology|June 11, 2008
Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myelomaNikhil C Munshi, Constantine Mitsiades, Paul G Richardson, et al.
Leukemia|May 20, 2020
Proteomic analysis identifies mechanism(s) of overcoming bortezomib resistance via targeting ubiquitin receptor Rpn13Ting Du, Yan Song, Arghya Ray, et al.
British Journal of Haematology|June 27, 2007
A strategic framework for novel drug development in multiple myelomaKenneth C Anderson, Alison L Hannah, Richard Pazdur, et al.
British Journal of Haematology|September 10, 2011
Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disordersJooeun Bae, Yu-Tzu Tai, Kenneth C Anderson, et al.
Oncology (Williston Park, N.Y.)|April 2, 2014
The heavy chain diseases: clinical and pathologic featuresGiada Bianchi, Kenneth C Anderson, Nancy Lee Harris, et al.
Nature Reviews. Clinical Oncology|November 26, 2014
Current treatment landscape for relapsed and/or refractory multiple myelomaMeletios A Dimopoulos, Paul G Richardson, Philippe Moreau, et al.
Pageof 87